Chemoattractant and opsonic activity in ascitic fluid. A study in 47 patients with cirrhosis or malignant peritonitis. 1991

F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
Service d'Hépato-Gastroentérologie, Hôpital Jean Verdier, Bondy, France.

We studied prospectively the ascitic fluid of 47 patients. Thirty-five were cirrhotics (group A) and 12 had malignant peritonitis (group B). All ascitic fluid samples were initially uninfected. We measured opsonic activity by a chemiluminescent assay, and chemoattractant activity by the under agarose technique. We also measured ascitic concentrations of C3, C4, fibronectin, C-reactive protein, immunoglobulins G, A and M and total proteins. All patients were followed throughout the presence of ascites. None of the group B patients developed peritoneal infection, nor did 23 of the group A patients (group A2). Twelve group A patients (group A1) developed spontaneous bacterial peritonitis (SBP), four of them with recurrence. All indices except immunoglobulins A and M were significantly different between group A and group B patients. Comparing group A1 and group A2, only chemoattractant activity and concentrations of total proteins and C3 were significantly lower in group A1. Using a multivariate analysis with Cox's model, only C3 concentration had an independent predictive value for occurrence of SBP in cirrhotic patients.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009895 Opsonin Proteins Proteins that bind to particles and cells to increase susceptibility to PHAGOCYTOSIS, especially ANTIBODIES bound to EPITOPES that attach to FC RECEPTORS. COMPLEMENT C3B may also participate. Opsonin,Opsonin Protein,Opsonins,Protein, Opsonin
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002630 Chemotactic Factors Chemical substances that attract or repel cells. The concept denotes especially those factors released as a result of tissue injury, microbial invasion, or immunologic activity, that attract LEUKOCYTES; MACROPHAGES; or other cells to the site of infection or insult. Chemoattractant,Chemotactic Factor,Chemotaxin,Chemotaxins,Cytotaxinogens,Cytotaxins,Macrophage Chemotactic Factor,Chemoattractants,Chemotactic Factors, Macrophage,Macrophage Chemotactic Factors,Chemotactic Factor, Macrophage,Factor, Chemotactic,Factor, Macrophage Chemotactic
D002633 Chemotaxis The movement of cells or organisms toward or away from a substance in response to its concentration gradient. Haptotaxis
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005260 Female Females

Related Publications

F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
January 1988, Hepatology (Baltimore, Md.),
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
March 1992, Journal of hepatology,
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
January 1986, Hepatology (Baltimore, Md.),
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
January 1985, Hepatology (Baltimore, Md.),
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
June 1983, The Journal of infectious diseases,
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
May 1985, Minerva chirurgica,
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
September 2023, Clinical and translational gastroenterology,
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
December 2021, Georgian medical news,
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
October 2002, Southern medical journal,
F Mal, and T P Huu, and M Bendahou, and J C Trinchet, and M Garnier, and J Hakim, and M Beaugrand
June 1986, Soins; la revue de reference infirmiere,
Copied contents to your clipboard!